{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:35:53Z","timestamp":1776479753684,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China Capital Characteristic Clinic Project","award":["Z211100002921037"],"award-info":[{"award-number":["Z211100002921037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00277-023-05502-0","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:03:13Z","timestamp":1697518993000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Xinhong","family":"Fei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"5502_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000447076","volume":"43","author":"G Juliusson","year":"2016","unstructured":"Juliusson G, Hough R (2016) Leukemia. Prog. Tumor Res 43:87\u2013100","journal-title":"Tumor Res"},{"issue":"8","key":"5502_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A (2020) Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol 21(8):66","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"5502_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M et al (2015) How I treat refractory and early relapsed acute myeloid leukemia. Blood 126(3):319\u2013327","journal-title":"Blood"},{"issue":"30","key":"5502_CR4","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","volume":"28","author":"RF Schlenk","year":"2010","unstructured":"Schlenk RF, Dohner K, Mack S et al (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28(30):4642\u20134648","journal-title":"J Clin Oncol"},{"issue":"23","key":"5502_CR5","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730\u20133738","journal-title":"J Clin Oncol"},{"issue":"1","key":"5502_CR6","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M et al (2023) A review of treatment options employed in relapsed\/refractory AML. Hematology 28(1):2196482","journal-title":"Hematology"},{"issue":"3","key":"5502_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/1042819021000035608","volume":"44","author":"T Robak","year":"2003","unstructured":"Robak T (2003) Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 44(3):391\u2013409","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"5502_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3816\/CLM.2009.n.058","volume":"9","author":"MG Martin","year":"2009","unstructured":"Martin MG, Welch JS, Augustin K et al (2009) Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma 9(4):298\u2013301","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"5502_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000493250","volume":"141","author":"L Wang","year":"2019","unstructured":"Wang L, Xu J, Tian X et al (2019) Analysis of efficacy and prognostic factors of CLAG treatment in Chinese patients with refractory or relapsed acute myeloid leukemia. Acta Haematol 141(1):43\u201353","journal-title":"Acta Haematol"},{"issue":"7","key":"5502_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12094-017-1798-8","volume":"20","author":"Y Bao","year":"2018","unstructured":"Bao Y, Zhao J, Li ZZ (2018) Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study. Clin Transl Oncol 20(7):870\u2013880","journal-title":"Clin Transl Oncol"},{"issue":"39","key":"5502_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012102","volume":"97","author":"J Xu","year":"2018","unstructured":"Xu J, Lv TT, Zhou XF et al (2018) Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: a retrospective cohort study. Medicine (Baltimore) 97(39):e12102","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"5502_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/bmt.2011.69","volume":"47","author":"SM Luger","year":"2012","unstructured":"Luger SM, Ringden O, Zhang MJ et al (2012) Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 47(2):203\u2013211","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"5502_CR13","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringden","year":"2009","unstructured":"Ringden O, Labopin M, Ehninger G et al (2009) Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 27(27):4570\u20134577","journal-title":"J Clin Oncol"},{"issue":"8","key":"5502_CR14","first-page":"624","volume":"42","author":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association","year":"2021","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association (2021) Chinese guidelines for the diagnosis and treatment of relapsed\/refractory acute myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi 42(8):624\u2013627","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"5502_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","volume":"38","author":"XJ Huang","year":"2006","unstructured":"Huang XJ, Liu DH, Liu KY et al (2006) Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38(4):291\u2013297","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"5502_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291","journal-title":"Blood"},{"key":"5502_CR17","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP (2017) Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 36:4391\u20134400","journal-title":"Stat Med"},{"issue":"4","key":"5502_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"18","key":"5502_CR19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Rosenblat T, Arellano M et al (2014) International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol 32(18):1919\u20131926","journal-title":"J Clin Oncol"},{"issue":"1","key":"5502_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clml.2022.08.014","volume":"23","author":"A Kopinska","year":"2023","unstructured":"Kopinska A, Weglarz P, Koclega A et al (2023) Allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a single-centre experience. Clin Lymphoma Myeloma Leuk 23(1):28\u201339","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5502_CR21","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/leu.2013.208","volume":"27","author":"E Todisco","year":"2013","unstructured":"Todisco E, Ciceri F, Oldani E et al (2013) The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia 27(10):2086\u20132091","journal-title":"Leukemia"},{"issue":"6","key":"5502_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjh.15137","volume":"180","author":"NK Steckel","year":"2018","unstructured":"Steckel NK, Groth C, Mikesch JH et al (2018) High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 180(6):840\u2013853","journal-title":"Br J Haematol"},{"issue":"6","key":"5502_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41409-022-01626-5","volume":"57","author":"F Bonifazi","year":"2022","unstructured":"Bonifazi F, Pavoni C, Peccatori J et al (2022) Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone Marrow Transplant 57(6):949\u2013958","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"5502_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1517\/13543780903071038","volume":"18","author":"S Spurgeon","year":"2009","unstructured":"Spurgeon S, Yu M, Phillips JD et al (2009) Cladribine: not just another purine analogue? Expert Opin Investig Drugs 18(8):1169\u20131181","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"5502_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ajh.23862","volume":"90","author":"CW Freyer","year":"2015","unstructured":"Freyer CW, Gupta N, Wetzler M et al (2015) Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol 90(1):62\u201372","journal-title":"Am J Hematol"},{"issue":"1","key":"5502_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1042819021000054670","volume":"44","author":"KU Chow","year":"2003","unstructured":"Chow KU, Boehrer S, Napieralski S et al (2003) In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 44(1):165\u2013173","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"5502_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4149\/neo_2021_210426N573","volume":"68","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zhang J, Long B et al (2021) A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed\/refractory acute myeloid leukemia. Neoplasma 68(6):1351\u20131358","journal-title":"Neoplasma"},{"issue":"17","key":"5502_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010228","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang J, Zhao J, Fei X et al (2018) A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Medicine (Baltimore) 97(17):e0228","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"5502_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.bmt.1705207","volume":"37","author":"AA Oyekunle","year":"2006","unstructured":"Oyekunle AA, Kroger N, Zabelina T et al (2006) Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant 37(1):45\u201350","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"5502_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.bmt.1705011","volume":"36","author":"C Hosing","year":"2005","unstructured":"Hosing C, Saliba RM, Shahjahan M et al (2005) Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36(2):157\u2013162","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"5502_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","volume":"26","author":"M Michallet","year":"2000","unstructured":"Michallet M, Thomas X, Vernant JP et al (2000) Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 26(11):1157\u20131163","journal-title":"Bone Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05502-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05502-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05502-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:03:51Z","timestamp":1704218631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05502-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5502"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05502-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Biomedical Ethics Committee of Aerospace Center Hospital and performed in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient approval statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}